Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Leases (2016 - 2025)

ImmunityBio (IBRX) has disclosed Current Leases for 10 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 0.92% to $7.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.5 million, a 0.92% increase, with the full-year FY2025 number at $7.5 million, up 0.92% from a year prior.
  • Current Leases was $7.5 million for Q4 2025 at ImmunityBio, up from $7.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $7.5 million in Q4 2025 to a low of $1.4 million in Q3 2022.
  • A 5-year average of $4.3 million and a median of $3.5 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: tumbled 55.57% in 2022, then soared 326.21% in 2023.
  • ImmunityBio's Current Leases stood at $3.0 million in 2021, then dropped by 11.99% to $2.6 million in 2022, then surged by 97.89% to $5.2 million in 2023, then skyrocketed by 42.37% to $7.5 million in 2024, then rose by 0.92% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Current Leases are $7.5 million (Q4 2025), $7.5 million (Q1 2025), and $7.5 million (Q4 2024).